Imagepace, Cincinnati, Ohio, USA.
Clin Pharmacol Ther. 2012 Feb;91(2):315-20. doi: 10.1038/clpt.2011.286. Epub 2012 Jan 4.
The early clinical drug development process increasingly utilizes imaging biomarkers to provide key information in response to a sequential series of questions about potential therapeutic agents. We present several examples of how imaging can answer some of these questions pertaining to the central nervous system (CNS) during the early phases of development of drugs to treat diseases involving the CNS. We also present an overview of the challenges and the potential of using and further qualifying imaging biomarkers for clinical trials.
早期临床药物开发过程越来越多地利用成像生物标志物来提供关键信息，以回答关于潜在治疗药物的一系列问题。我们介绍了一些例子，说明在开发治疗中枢神经系统（CNS）疾病的药物的早期阶段，成像如何回答与 CNS 相关的一些问题。我们还概述了使用和进一步确定成像生物标志物进行临床试验的挑战和潜力。
